VestGen Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD

VestGen Advisors LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 93.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,866 shares of the biopharmaceutical company’s stock after selling 25,709 shares during the period. VestGen Advisors LLC’s holdings in Gilead Sciences were worth $207,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Activest Wealth Management increased its holdings in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $27,000. Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares in the last quarter. Finally, Colonial Trust Advisors grew its position in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research analyst reports. TD Cowen lifted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Citigroup upped their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $130.65.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the transaction, the chief executive officer owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This trade represents a 1.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the sale, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. This represents a 20.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 135,757 shares of company stock valued at $16,616,127 over the last ninety days. 0.27% of the stock is owned by insiders.

Gilead Sciences Trading Up 0.9%

GILD opened at $125.00 on Thursday. The stock has a market capitalization of $155.09 billion, a PE ratio of 19.38, a P/E/G ratio of 0.69 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $88.57 and a one year high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The business’s 50 day moving average price is $120.53 and its 200 day moving average price is $115.09.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.